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Spirometry is not enough to diagnose COPD in
epidemiological studies: a follow-up study
Elena Andreeva1,2, Marina Pokhaznikova3, Anatoly Lebedev3, Irina Moiseeva3, Olga Kuznetsova3 and Jean-Marie Degryse 1,4
A hallmark of the diagnosis of chronic obstructive pulmonary disease (COPD) is the measurement of post-bronchodilator (post-BD)
airﬂow obstruction (AO) by spirometry, but spirometry is not enough for the provision of a clinical diagnosis. In the majority of
previous epidemiological studies, COPD diagnosis has been based on spirometry and a few clinical characteristics. The aim of our
study was to identify outcomes in patients newly diagnosed with airﬂow obstruction (AO) based on a diagnostic work-up
conducted as part of a population-based cross-sectional study in North-Western Russia. Spirometry was performed before (pre-BD)
and after BD administration, and AO was deﬁned using the FEV1/FVC <0.70 and FEV1/FVC <lower limit of normal cut-off values.
Relevant symptoms were recorded. Participants with AO identiﬁed at baseline were then examined by a pulmonologist, including a
clinical examination and second spirometry with BD test. Of the 102 participants with post-BD AO in the initial assessment, only
60.8% still had AO identiﬁed at the second examination; among these patients, the following ﬁnal diagnoses were reported: COPD
(n = 41), asthma (n = 5), asthma–COPD overlap syndrome (ACOS) (n = 4) and likely ACOS (n = 5). Of the 65 participants with pre-BD
AO, 23.1% had post-BD AO at the second assessment, and these patients had been diagnosed with COPD (n = 12), asthma (n = 1),
ACOS (n = 1), likely ACOS (n = 1). Serial spirometric assessments complemented by a comprehensive clinical evaluation are
recommended in new epidemiological studies.
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INTRODUCTION
Although chronic obstructive pulmonary disease (COPD) is, at
present, the third most prevalent cause of death in developed
countries and associated with increasing mortality in developing
countries, this conditions is still not well recognized by either the
general public or physicians, and over half of COPD cases go
undiagnosed.1 The rates of COPD prevalence, morbidity, and
mortality vary across countries and different groups within
countries.2 According to the Burden of Obstructive Lung Disease
study, the prevalence of stage II or higher COPD was 10.1% overall
(from 5.9% in Germany to 19.1% in South Africa), 11.8% in men,
and 8.5% in women, mainly increasing with age and smoking
exposure.3
In 2011, the European Respiratory Society (ERS) task force report
entitled “Recommendations for Epidemiological Studies of COPD”
was published with the aim of establishing clear diagnostic criteria
and standardized methods to examine COPD.4 The authors
strongly recommended measuring as many different character-
istics of COPD patients (e.g., respiratory symptoms, exacerbation
frequency, comorbidity assessment, body mass index (BMI),
biological markers, chest radiography, and risk factors assessment)
as possible, in addition to spirometry, to provide a better
understanding of the disease.4
There are several different problems related to the diagnosis of
COPD. The lack of consensus on its deﬁnition should be given
primary consideration. Several deﬁnitions coexist, but no one
deﬁnition is preferred over the others.5 COPD has been deﬁned as
a complex and heterogeneous syndrome with pulmonary and
extrapulmonary features;2 as a variety of different clinical
syndromes based on the presence of symptoms, measures of
airﬂow obstruction (AO) and reversibility;5,6 or as a heterogeneous
collection of diseases with different causes, pathogenic mechan-
isms, and physiological effects.7 The guidelines of the Global
Initiative of Chronic Obstructive Lung Disease (GOLD) deﬁned
COPD in 2016 as “a common, preventable and treatable disease
characterized by persistent airﬂow limitation that is usually
progressive, and associated with an enhanced chronic inﬂamma-
tory response in the airways and the lungs to noxious particles or
gases. Exacerbations and comorbidities contribute to the overall
severity in individual patients”.2
Another problem is the use of different COPD deﬁnitions in
epidemiological and case-ﬁnding studies. Moreover, COPD deﬁni-
tions within each type of study have also varied. As recommended
by several recent international guidelines or research initiatives,
standardization of the epidemiological deﬁnition of COPD is one
of the key elements necessary for the estimation of COPD
prevalence.8 There is signiﬁcant heterogeneity in the estimation of
COPD prevalence, even in well-designed epidemiologic studies,
due to the diverse methodological approaches applied to COPD
deﬁnition and diagnostics, investigation methods used, and target
populations studied.8,9 Even when using data from the same
study, different deﬁnitions and exclusion criteria can result in
different estimates of COPD prevalence.9 A similar problem can be
observed in studies evaluating case-ﬁnding strategies for COPD.10
A standardized epidemiological deﬁnition of COPD is needed to
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conduct high-quality randomized controlled trials designed to
compare target populations, recruitment strategies, and screening
tests.11
The third issue is the absence of a gold standard AO cut-off
value. The two most frequently used values are as follows: a ﬁxed
ratio of 0.7 (a ratio of the forced expiratory volume in 1 s to the
forced vital capacity, FEV1/FVC <0.7) and a FEV1/FVC ratio below
the ﬁfth percentile of a large healthy reference group (the
statistically deﬁned lower limit of normal, LLN).2 This case-ﬁnding
strategy assumes that spirometry has been performed on patients
with risk factors and respiratory symptoms and that if AO (with
ﬁxed ratio FEV1/FVC <0.70) is identiﬁed, a diagnosis of COPD will
be conﬁrmed unless patients have other respiratory diseases, such
as asthma, bronchiectasis, or stenosing bronchial tumors.5
The LLN cut-off has been the preferred measure for use in
epidemiological settings, as it is the physiologists’ choice and uses
a deﬁnition based on normality.4,5 In the clinical setting, the ﬁxed
cut-off is more simple and familiar, but it is difﬁcult to choose one
appropriate cut-off because of absence of comparative studies.5
Using the ﬁxed cut-off, the COPD prevalence is often higher than
it is when estimated using the LLN cut-off.9 Sex differences in the
risk of COPD are also inﬂuenced when the ﬁxed cut-off deﬁnition
is used for diagnosing COPD; no such difference has been found
when using the LLN deﬁnition.12
The next important issue in COPD diagnosis is the uncertainty of
diagnosis over time, as an individual can be diagnosed with mild
COPD at ﬁrst assessment but have normal spirometry results at
follow-up, even without intervention.13 Both the forced expiratory
volume in one second (FEV1) and the forced vital capacity (FVC)
can vary over time.13 There is still room for improvement in the
diagnostic work-up of COPD, such as deﬁning a cut-off value using
a ratio of the FEV1 to the forced expiratory volume in 6 s (FEV1/
FEV6) <LLN, deﬁning a borderline zone around the LLN, or
repeating spirometry for patients with borderline results.13
The ERS task force also recommends the assessment of various
COPD phenotypes.4 One of these phenotypes is asthma–COPD
overlap syndrome (ACOS), which was recently presented in the
Global Strategy for Diagnosis, Management and Prevention of
COPD (GOLD).2 ACOS is characterized by clinical features common
to both asthma and COPD, which makes the diagnosis of COPD
even more challenging.2 The characterization of ACOS, which
currently has different deﬁnitions, remains preliminary, which
might lead to heterogeneous estimates of ACOS prevalence.14
This is aggravated by the fact that both asthma and COPD are
heterogeneous diseases with substantial inter-individual variabil-
ity, and varied pathogenic mechanisms and risk factors.15 In
addition, large population studies have found that a high
proportion of patients with respiratory problems may be classiﬁed
as having more than one diagnosis.9
To summarize, the key issues regarding the diagnosis of COPD
include different COPD deﬁnitions, a gap between the “epide-
miological” deﬁnition and the “clinical deﬁnition” of COPD,
two proposed FEV1/FVC cut-off values for deﬁning AO, and
uncertainty in the diagnosis over time and as it relates to ACOS.
Further studies are needed to combine the epidemiological
and clinical perspectives and, thus, to improve the diagnosis
of COPD.
Recently, we reported for the ﬁrst time the prevalence of AO in
adults aged 35–70 years in two northwestern cities in Russia
using both the ﬁxed and LLN (by the Global Lung Initiative (GLI)
2012 reference equations) cut-off values; additionally, we
identiﬁed risk factors and assessed the diagnostic value of
respiratory symptoms for AO (“The RESearch on the PrEvalence
and diagnosis of COPD and its Tobacco-related etiology”,
RESPECT study).16,17 This article reports the ﬁndings of a follow-
up diagnostic assessment performed by a pulmonologist on
those identiﬁed as having AO during the baseline assessment of
the RESPECT study.
RESULTS
Of the 3133 individuals included in the RESPECT study, 2974 had
satisfactory pre-BD and 2388 had satisfactory post-BD spirometry.
All 278 individuals with pre-BD and pre + post-BD AO based on
the ﬁxed or GLI–LLN cut-off values were invited to participate in
this diagnostic study; of these patients, 177 agreed to participate
and 167 had satisfactory post-BD spirometry (Fig. 1). The mean
interval between the baseline and the second spirometry tests
was 14.5 ± 4.8 months (ranging from 4 to 27 months).
The mean age of the participants was 56.6 years; of the
participants, 51.5% were male and 74.3% were current or ex-
smokers. The baseline characteristics of the study population,
including BD test results and seven diagnostic categories based on
clinical and spirometric criteria, are presented in Table 1.
There was no signiﬁcant difference between the health statuses
of participants who had AO identiﬁed during the follow-up
spirometry measurement and those who did not. Overall, 37.3% of
those who had and 27.6% of those who did not have AO reported
that their health status had worsened during the last year (p =
0.23).
Of the 167 participants with AO observed during the ﬁrst
spirometry examination, 46.1% had post-BD AO identiﬁed during
the second spirometry examination (23.1% of those with pre-BD
AO and 60.8% of those with post-BD AO during the ﬁrst
spirometry examination) (Fig. 1). The participants with pre-BD
and post-BD AO identiﬁed based on both FEV1/FVC cut-offs had
mainly been diagnosed as having COPD (68.8%), ACOS or likely
ACOS (19.5%), and asthma with ﬁxed obstruction (7.8%) (Fig. 1).
Among those without AO identiﬁed during the second spirometry
examination, 35 participants (38.9%) had been diagnosed with no
objective evidence of obstructive lung disease. The other main
diagnostic categories were asthma (26.7%) and chronic bronchitis
(22.2%). The participants with post-BD AO tended to more often
be male (61%), older (mean age 58.6 ± 6.84 years) and smokers/ex-
smokers (83.1%) compared to participants without AO. There were
no statistically signiﬁcant differences between the AO categories
regarding occupational hazards (dusty or gas/chemical fumes
exposure for more than 10 years). Forty-seven percent of the
participants with AO did not report a diagnosis of any chronic
respiratory disease, and 26% of those with AO did not report any
chronic respiratory symptoms.
The FEV1/FVC ratio measured during the baseline spirometry
was lower among the 62 participants who had post-BD AO
identiﬁed both during the ﬁrst and second spirometry measure-
ments than among the 40 participants without AO identiﬁed
during the second spirometry measurement (FEV1/FVC = 0.60
[95% CI 0.57–0.65) and FEV1/FVC = 0.66 [95% CI 0.65–0.67],
correspondently, p < 0.01). These 62 participants were older than
the other 40 participants (mean ages of 59.5 ± 6.6 and 56.3 ± 8.8
years reported at baseline spirometry, respectively, p = 0.000) and
tended to be male (61.3 vs. 50%, p = 0.32).
The positive predictive values (PPVs) of the syndrome including
all the chronic respiratory symptoms and of chronic cough and
dyspnea separately was low for the diagnosis of COPD (and “likely
COPD”), asthma, ACOS and chronic bronchitis (Table 2).
We tabulated participants with a diagnosis of AO at baseline by
GOLD class in order to compare how many changed diagnosis
after the second assessment in each class (supplementary table 1).
We found that 60% of those that shifted diagnosis from
obstructive to non-obstructive were labeled as GOLD class 1
before and another 37,5% as GOLD class 2
In order to identify which patients would require serial
spirometry, we compared the background characteristics at
baseline of two subgroups: those that remained obstructed after
the second assessment and those that presented a shift from
obstructive to non-obstructive (see the supplementary table 2).
We found that those who shifted from non-obstructive were older
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had lower FEV1 and FEV1/FVC values, and had less frequently a
history of a respiratory disease. However, none of these
characteristics allow us to identify a subgroup in a reliable way.
DISCUSSION
Main ﬁndings
In our population-based, cross-sectional sample of adults aged
35–79 years in two northwestern cities in Russia, less than half of
those with AO identiﬁed during the ﬁrst spirometry examination
had post-BD AO identiﬁed during the second spirometry
examination. Patients with AO based on both FEV1/FVC cut-off
values had mainly been diagnosed with COPD, ACOS, likely ACOS,
and asthma with ﬁxed obstruction. A quarter of all the study
participants with AO did not report any chronic respiratory
symptoms. The PPV of all the respiratory symptoms for the main
obstructive (COPD, asthma, ACOS) and non-obstructive (chronic
bronchitis) respiratory diseases was low.
This study had three essential ﬁndings. First, there was a gap
between the “epidemiological” deﬁnition (as shown in the
baseline RESPECT study) and the “clinical” deﬁnition of COPD (as
shown in the diagnostic follow-up of the RESPECT study). Second,
variability in spirometric values (due to biological and/or
measurement error), including pre-BD and post-BD values, was
identiﬁed. Third, one spirometric assessment was not enough for
COPD diagnosis. Serial longitudinal spirometric assessments are
needed and should be complemented by a comprehensive
clinical assessment when diagnosing COPD.
Comparison with other studies
The difference between epidemiological deﬁnitions based on
spirometry only and clinical deﬁnitions considering symptoms and
risk factors. In the majority of previous epidemiological studies,
COPD diagnosis has been based on spirometry and a few clinical
characteristics, e.g., the absence of self-reported respiratory
disease, such as asthma.4 One of the main pivotal differences
between the epidemiological and clinical diagnosis of COPD is a
doctor’s evaluation of risk factors (e.g., smoking history, environ-
mental and occupational hazards), symptoms, and spirometry.4
Clinical signs and symptoms, such as dyspnea, cough and mucus
production, often vary widely on an individual basis among
patients with the same degree of AO.18 Systemic inﬂammation
and other clinical manifestations associated with AO may not be
captured by FEV1 changes over time but are likely to impact an
individual’s clinical severity.18
Spirometric evaluation itself may be diagnostic only when
values distant from normality are observed.19 The diagnosis of
COPD is not difﬁcult to assign when values of FEV1/FVC and FEV1
are far from normal, and a patient has respiratory signs and
symptoms and known risks factors.19 The key dilemma for
clinicians is COPD diagnosis when these values are only slightly
below the be predicted values (for example, the “gray zone” for
FEV1/FVC = 0.70–0.80). The following scenarios have previously
been considered.19 To conﬁrm the diagnosis of COPD in a subject
who has never smoked and has no symptoms, the clinician needs
a “no doubt spirometry” result showing AO in a subject who has
been exposed to occupational hazards or is an athlete with a high
level of cardiovascular and neuromuscular ﬁtness.19 If the subject
is a current smoker with a history of 70 pack-years and reports
chronic cough, phlegm and breathlessness upon moderate effort
and has no evidence of chronic heart disease, a more accurate
measurement of lung volumes using plethysmography and
diffusion capacity is needed to rule out the diagnosis of COPD
when FEV1/FVC > 0.70. In this case, it has been suggested to use
“clinical” criterion rather than another cut-off value (FEV1/FVC
below LLN).19
Our study exempliﬁed the differences between epidemiological
and clinical perspectives. Of all the participants diagnosed with AO
during the ﬁrst spirometry examination, only 60.8% had evidence
of AO observed during the second post-BD spirometry examina-
tion. These participants were older (59.5 ± 6.6. years and 56.3 ± 8.8
Fig. 1 The RESPECT Diagnostic Study Flow Diagram
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years, respectively), and had a lower ratio FEV1/FVC observed
during the baseline spirometry assessment than did those without
AO observed during the second assessment (FEV1/FVC = 0.60 and
FEV1/FVC = 0.66, respectively). Of the 62 participants with post-BD
AO observed at both the baseline and the second spirometry
measurements, 41 (66.1%) had a clinically conﬁrmed diagnosis of
COPD, and 13 patients (20.9%) had been diagnosed with ACOS
and likely ACOS.
The difference between using pre-BD or post-BD spirometry in
epidemiological studies. Post-BD spirometric values and the LLN
deﬁnition have been recommended as the diagnostic criteria to
be used when deﬁning COPD in epidemiological studies.4
Nevertheless, only pre-BD spirometry testing has been used in
some recently published studies.20 However, in some other
studies, signiﬁcant differences in COPD prevalence were identiﬁed
when COPD was diagnosed based on pre-BD and post-BD
spirometry measurements.21,22 As was demonstrated in the
National Health and Nutrition Examination Survey 2007–2010,
COPD prevalence among adults aged 40–79 years based on pre-
BD measurements was 20.9%, whereas the prevalence based on
post-BD measurements was 14.0%.21 Similar differences were
identiﬁed when using the LLN criteria (pre-BD prevalence was
15.4% and post-BD one was 10.2%).21 The results of a community-
based health checkup study (the Hisayama Study) also supported
the aforementioned ﬁndings (COPD prevalence rate based on pre-
BD measurements was 14.6% in males and 13.7% in females and
the rate based on post-BD measurements was 8.7 and 8.7%,
respectively).22 The authors concluded that the use of post-BD
spirometry in health checkups “would reduce the number of
subjects with probable COPD by one-third”.22
This difference was also demonstrated in the previously
published results of the RESPECT study.17 In that study, the pre-
BD and post-BD AO prevalence rates were 8.3 and 6.8% according
to the ﬁxed cut-off value and 5.9 and 4.8% according to GLI–LLN
cut-off value, respectively.17 In the current study, it is demon-
strated that the prevalence rates of pre-BD and post-BD AO
changed over time, even without intervention.
Difference between using only one spirometry measure and repeated
measures for COPD diagnosis. In epidemiological studies, atten-
tion has mainly focused on cross-sectional assessments and the
inﬂuence of COPD criteria on population prevalence; however, the
consistency of COPD diagnosis is no less important for patients
than are clear spirometric criteria.13 There are known and
expected variations in spirometric results after repeated testing
(due to biological variability and/or measurement errors).23 The
aforementioned variations and systematic changes due to aging
may result in changes in the diagnosis of COPD over time.13,24
Based on the GOLD criterion,2 a person with an FEV1/FVC = 0.69
would be diagnosed with COPD; however, if the same person had
a ratio of 0.7 obtained during a follow-up exam, he/she would no
longer be diagnosed as having COPD.13 However, the current
recommendation for COPD diagnosis only takes into account a
single spirometry measurement,2 and does not take longitudinal
inconsistencies into consideration.13
The recently published results of baseline and follow-up studies
conducted as part of a multicenter prevalence survey of COPD in
major Latin American cities (the PLATINO study) have described
the rates and correlates of inconsistent interpretations of AO
according to its several criteria.13 The follow-up studies were
conducted 5–9 years after the baseline surveys were performed.13
The following three main ﬁndings may be derived from these
studies: (1) regardless of which AO criterion was used, incon-
sistencies in COPD diagnosis were observed (the LLN deﬁnition or
deﬁned as FEV1/FVC < 0.7 using the GOLD criteria plus FEV1 < 80%
of the value predicted for GOLD stages 2–4 or FEV1 < LLN); (2)
depending on which AO criterion was used, COPD prevalence
would be lower or higher and, therefore, less or more inconsistent
upon repeated testing (the FEV1/FVC deﬁnition was less
concordant when tested twice than was the FEV1/FEV6 deﬁnition,
while the consistency of COPD diagnosis was highest when using
the FEV1/FEV6<LLN deﬁnition and for deﬁnitions of airﬂow
obstruction requiring a low FEV1 (GOLD stage 2–4); and (3) the
closer the FEV1/FVC, FEV1/FEV6 and FEV1 were to the cut points,
the higher the possibility of a change in diagnosis upon repeated
testing.13
The interval between the baseline and follow-up spirometry
measurements was shorter in our study than in the aforemen-
tioned study (14.5 ± 4.8 months and 5–9 years, respectively). No
signiﬁcant deterioration in health status was observed during this
time interval.
In our study, 23.1% of those who did not have post-BD AO
observed during the ﬁrst spirometry were identiﬁed as having
post-BD AO during the second spirometry measurement. Those
who did not have post-BD AO observed during the ﬁrst
assessment but had AO identiﬁed at follow-up and those who
maintained a non-obstructed airway had similar smoking statuses
(86.7 and 66.0% current/ex-smokers, respectively, p = 0.24). Similar
results were derived among those who had post-BD AO observed
at baseline regardless of the follow-up spirometry results (82.3%
current/ex-smokers among those with AO at both timepoints and
69.2% among those who did not AO observed at follow-up, p =
0.2).
We observed that participants who had AO observed at
baseline and during the follow-up spirometry measurement pre-
sented a lower ratio FEV1/FVC during baseline spirometry than
those who had “reversed” AO.
Of the participants with post-BD obstruction observed during
the follow-up spirometry measurement, 47% did not report a
diagnosis of any chronic respiratory disease and 26.0% did not
report any chronic respiratory symptoms.
Thus, the use of serial longitudinal spirometric assessments
seems to be an essential factor in ensuring the stability of COPD
diagnoses and should be complemented with comprehensive
clinical assessments.
Irreversible airway obstruction: COPD, asthma or ACOS? The GOLD
has recently introduced a classiﬁcation and assessment criteria for
different COPD phenotypes, and this introduction has been
reﬂected in several studies employing multidimensional grading
systems, such as the BODE (BMI, airﬂow obstruction, dyspnea and
exercise capacity) and other systems aiming to “simplify the
complex diagnosis” of a COPD patient.2,18
It has been increasingly recognized that both asthma and COPD
are heterogeneous diseases with substantial inter-individual
variability with regards to their clinical expression and disease
progression.15 However, there remains a need for a clear
distinction between COPD and the irreversible form of asthma.
Before the publication of the consensus statement by Global
Initiative for Asthma (GINA) and GOLD concerning the diagnosis,
assessment, and treatment of ACOS,25 there was no clear
deﬁnition for this overlapping syndrome.26 For example, irrever-
sible obstruction in long-smokers was called never-smoker COPD,
despite being mainly attributable to asthma.27 Another common
belief was that COPD and irreversible asthma in smokers could not
be differentiated.28 In addition, the division of the ACOS
phenotype into the two following clinical sub-phenotypes was
suggested: (1) never-smokers, ex-smokers, or current smokers with
a history of asthma who have incompletely reversible AO
(asthma–ACOS); and (2) smokers or ex-smokers with COPD
diagnosed according to the GOLD criteria who display increased
bronchodilator reversibility or bronchial hyperresponsiveness
(COPD–ACOS).15
The prevalence of ACOS varies by geographic region and
clinical setting (primary or specialist care), and is believed to be
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high, partially because of the lack of a consistent diagnosis.29 It
has been estimated that ACOS is present in 15–45% of the
population with obstructive airway disease and is believed that
the prevalence of ACOS increases with age.30–32 Patients with
ACOS tend to be older than those with asthma; additionally, they
often have a long smoking history, present with asthmatic
features, and have persistent AO.29 The most recent review article
published in the New England Journal of Medicine stated that it
would be “premature to recommend the designation of ACOS as a
disease entity in primary and specialist care.”32 Thus, it is essential
to better characterize patients with and obtain a standardized
deﬁnition of ACOS, and a further research is one way to achieve
these objectives.32
In our study, we used two ACOS deﬁnitions based on the
current guidelines,25 as follows: (1) ACOS: symptoms common to
both asthma and COPD, post-BD FEV1/FVC < 0.7 or GLI–LLN and
post-BD increase in FEV1 > 12% and 400 ml from baseline (marked
reversibility); and (2) likely ACOS: symptoms common to both
asthma and COPD, post-BD FEV1/FVC < 0.7 or GLI–LLN and post-
BD increase in FEV1 > 12% and 200ml from baseline (reversible
AO). The prevalence of both syndromes (ACOS and likely ACOS)
was 9.0% among participants who had AO observed during the
ﬁrst spirometry measurement. Patients with ACOS and likely ACOS
tended to be older and have persistent AO, and these patients had
the lowest FVC and FEV1 measures of all the study participants.
The PPV of chronic respiratory symptoms was rather low for all
ﬁnal diagnoses but the negative predictive value was high
(Table 2). Which means that in the absence of symptoms a
diagnosis of COPD/likely COPD, asthma, and chronic bronchitis is
highly unlikely. In clinical practice assessing symptoms as a ﬁrst
step might be a defensible strategy. But a word of caution is
needed here. The assessment of the diagnostic value of signs and
symptoms performed in our analysis might be affected by
inclusion bias, since the evaluation of those symptoms is part of
the ﬁnal diagnosis (=reference standard)
Strengths and Limitations. The RESPECT study is a prospective
population-based study of adults aged 35–70 years with the
following three components: a cross-sectional, a case-control and
a cohort study. This paper reports the ﬁndings of the cross-
sectional and cohort components of the RESPECT study. All
participants with pre-BD and post-BD AO based on both FEV1/FVC
cut-off values in the cross-sectional study were included in the
follow-up study and examined by an experienced pulmonologist
using a standardized comprehensive diagnostic work-up protocol.
Spirometry was performed before and after BD administration and
complied with the ATS/ERS standards of spirometry quality.
Our study also has some limitations. One limitation is the
participants who were lost to follow-up or refused to take part in
the second assessment. For the most part, these participants had
moved to other places or were unable to undergo spirometry, and
nine participants had died. An additional ten participants were
excluded due to low-quality measurements obtained during the
second assessment.
Due to ﬁnancial restrictions and a lack of availability in one of
the two cities where the RESPECT study is being conducted, some
functional respiratory tests, such as body plethysmography and
diffusion capacity, and computer tomography scans were not
performed. It should, however, be emphasized that the aim of this
study was to improve the diagnosis of AO in primary care settings,
which are the ﬁrst institutions at which patients with respiratory
symptoms may be seen.
The RESPECT study population differs from the overall popula-
tion of the northwestern region of Russia in terms of age and
sex.16 It has more women than the average population in the
northwestern region of Russia (68.2 vs. 55.3%) and less current and
ex-smokers than the average Russian population (47.8 vs.
53.9%).16 This might have led to a decreased amount of
participants being identiﬁed as having AO than would be
expected in the general population.
CONCLUSION
Single spirometry or clinical respiratory symptoms alone are not
enough for accurate COPD diagnosis. A comprehensive approach
including clinical assessment and follow-up spirometry should be
taken into consideration for the diagnosis and management of
COPD as well as for any screening program or prevalence study
conducted in the future.
METHODS
Study design and population
The RESPECT study is a population-based study that is being conducted as
a collaborative effort between the Université Catholique de Louvain
(Belgium), North-Western State Medical University (named for I. I. Mechnikov,
St. Petersburg, Russia) and Northern State Medical University, Arkhangelsk
(Russia). The study was designed to attain a better understanding of the
epidemiology of COPD in northwestern Russia. Descriptions of the design
of and rationale for the RESPECT study have already been published
elsewhere.16 Brieﬂy, 15 primary care centers in two northwestern Russian
cities (St. Petersburg and Arkhangelsk) were invited to participate in the
RESPECT study, and 15 investigators (10 from St. Petersburg and 5 from
Arkhangelsk) were recruited. The study population was comprised of
patients randomly selected from lists (organized based on territories)
provided by the 15 participating centers. Adults aged 35–70 years were
selected from each center using a random number generator and invited
to participate in the study. Participating sites agreed to recruit a
population-based random sample of at least 200 adults who were not
institutionalized, were 35–70 years old, and were living in a well-deﬁned
administrative area (16). The research investigators administered ques-
tionnaires regarding the participants’ background characteristics, including
sociodemographic data, smoking status, occupational exposures and
respiratory symptoms. All participants were invited to undergo spirometry.
The baseline characteristics of the total RESPECT population have already
been published elsewhere.16
Those with AO based on the ﬁxed and GLI–LLN cut-off values before
(pre-BD) and after (post-BD) bronchodilator administration were invited to
participate in this diagnostic study, which included undergoing examina-
tion by one of the two principal investigators, who are both experienced
pulmonologists, and pre-BD and post-BD spirometry measurement.
For the baseline study, patients were enrolled between June 8, 2012 and
December 17, 2013, and those who participated in the diagnostic study
were examined between May 16, 2013 and May 13, 2015.
The local medical ethics review boards approved the study protocol
(North-West State Medical University [named for I. I. Mechnikov], St.
Petersburg, protocol N 11 from 07.12.2011, and Northern State Medical
University, Arkhangelsk, protocol N 01/1-12 from 11.01.2012). All partici-
pants provided informed consent. Clinical trial registration: NCT02307799.
Methods were performed in accordance with relevant regulations and
guidelines.
Background characteristics and other variables
The background characteristics evaluated included sex, age and socio-
economic status. Smoking status was speciﬁed as “never smoked”, “ex-
smoker” (persons who had quit smoking ≥6 months prior), or “current
smoker”. Former and current smokers were asked to report the age at
which they began to smoke, how many years they had smoked and how
many cigarettes per day they had smoked (in pack-years). One pack-year of
smoking indicated that an individual smoked one pack of cigarettes (20
cigarettes) daily for one year. The American Thoracic Society (ATS) 1978
Adult Questionnaire (ATS-DLD-78) was used to assess exposure to
occupational hazards.33 The participants were asked if they had worked
for one year or more in any dusty job, a job with exposure to gas or
chemical fumes, and a job involving the use of protective equipment.
Information regarding any personal or family history of obstructive airway
disease (asthma, chronic bronchitis, emphysema, and chronic cough),
allergic diseases, or tuberculosis and the presence of co-morbidities were
collected systematically. History of hospitalization, treatment and exacer-
bation frequency of obstructive disease were assessed at enrollment.
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The comprehensive standardized assessment protocol used by the
pulmonologist included a physical examination with lung and heart
auscultation; measurement of height, weight, BMI, waist circumference,
pulse, respiratory rate, and blood pressure; and skin and edema
assessments. Patients were asked about the presence of chronic
respiratory symptoms, including chronic cough, sputum production
(deﬁned as lasting longer than 3 months), and dyspnea.34 A 3-level
version of the EuroQol 5-Dimension descriptive system (the EQ-5D-3 L) was
used as a standardized measure of health status.35,36
Spirometry
Spirometry was performed using a portable turbine Micro Spirometer (MIR
Spirobank, Rome, Italy) and a personal computer equipped with the
WiPam program to facilitate the uploading of data to a central database.
The accuracy of the spirometry measurements that were performed by
trained investigators has been previously reported.37 All investigators were
invited to participate in a 3-week distance-learning course on spirometry
with a 1-day face-to-face training session (SpiroCourse).38 All investigators
completed the course successfully and agreed to receive continuous
quality feedback on the performed tests.
Winspiro Pro software (MIR) was used to compare the measured values
with those in reference tables and to automatically calculate the
reproducibility of the performed spirometry in accordance with the ERS
guidelines. Both during the baseline assessment and this diagnostic study,
pre-BD and post-BD spirometry were performed using 400 μg of
salbutamol or 160 μg of ipratropium bromide (for the patients older than
60 years of age or with comorbid cardiovascular disease). The ATS/ERS
quality criteria were used to assess the acceptability and repeatability of
the results.23 All spirograms were evaluated by two independent experts
and classiﬁed into 4 categories (ATS1: all ATS/ERS criteria, including
reproducibility, are fulﬁlled; ATS2: all criteria except for duration of
expiration >6 s are fulﬁlled; ATS3: the test was “usable” for the
interpretation of the peak expiratory ﬂow and FEV1, and the spirograms
displayed good starts and no coughs during the 1st second of the
maneuver; and ATS4: none of the ATS/ERS criteria are fulﬁlled and
spirograms are not usable). Spirograms classiﬁed as ATS1 or ATS2 were
considered to be of acceptable quality for inclusion in this study.
The predictive values of the spirometry parameters were calculated
based on the GLI 2012 reference values using GLI 2012 Data Conversion
software.39 Pre-BD and post-BD AO was deﬁned using FEV1/FVC < 0.7 (ﬁxed
cut-off) and FEV1/FVC<GLI–LLN as cut-off values.
Statistical analysis
Descriptive statistics were calculated for all variables. Continuous variables
are presented as the mean ± standard deviation (SD), and categorical
variables are presented as numbers with frequencies.
After baseline spirometry was performed, the study population was
divided into the following two main AO categories: (1) participants with
pre-BD AO (FEV1/FVC < 0.7 and/or FEV1/FVC < GLI–LLN), and (2) partici-
pants with post-BD AO (FEV1/FVC < 0.7 and/or FEV1/FVC<GLI–LLN). After
the second spirometry with BD test, both categories were further divided
into the following subgroups: (a) participants with post-BD AO (FEV1/FVC
< 0.7 and/or FEV1/FVC<GLI–LLN); and (b) participants without AO
according to either cut-off value (FEV1/FVC≥ 0.70 or FEV1/FVC≥GLI–LLN).
With reference to clinical and spirometric criteria, participants were
assigned to one of the following mutually exclusive diagnostic categories:
(1) COPD, (2) likely COPD, (3) asthma, (4) ACOS, (5) likely ACOS, (6) chronic
bronchitis, (7) other diagnosis and (8) no objective evidence of obstructive
lung disease (Fig. 1). The diagnosis of obstructive disease was based on the
guidelines of GOLD (2), the GINA40 and the diagnosis of diseases of chronic
airﬂow limitation: asthma, COPD and ACOS25 (Fig. 2).
Statistical signiﬁcance was set at <0.05 (a two-tailed probability value).
SPSS version 20.0 (SPSS Inc., Chicago, IL, USA) was used for the statistical
analyses.
Data availability
The datasets generated and/or analyzed during the current study are
available from the corresponding author on reasonable request.
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COPD (chronic obstrucve pulmonary disease): paents with dyspnea, chronic cough or sputum 
producon, a history of exposure to risk factors for the disease and a post-BD FEV1/FVC < 0.70 or 
FEV1/FVC < GLI-LLN (based on the GOLD deﬁnion).
Likely COPD: paents with symptoms and risk factors of COPD but no AO observed (a post-BD 
FEV1/FVC > 0.7 or FEV1/FVC > GLI-LLN).
Asthma: paents with a history of respiratory symptoms such as wheezing, shortness of breath, 
chest ghtness and cough that vary over me and in intensity and variable expiratory airﬂow 
limitaons (at least one during the diagnosc process when FEV1 is low, documentaon that the 
FEV1/FVC rao is reduced; and BD reversibility, such as an increase in FEV1 by more than 12% and 
200 ml following BD inhalaon). 
Asthma-COPD overlap syndrome (ACOS): paents with the features common to both asthma and 
COPD and with post-BD FEV1/FVC < 0.7 or FEV1/FVC < GLI-LLN and post-BD increase in
FEV1 >12% and 400 ml from baseline (marked reversibility). 
Likely ACOS: paents with the features common to both asthma and COPD and with post-BD 
FEV1/FVC < 0.7 or FEV1/FVC < GLI-LLN and post-BD increase in FEV1 > 12% and 200 ml from baseline 
(reversible airﬂow limitaon).
Chronic bronchis: patients with a producve cough that lasts at least three months and with
recurring bouts occurring for at least two consecuve years.
FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; GLI-LLN: lower limit of normal determined as the 5th 
percenle of the z-scores of the reference populaon using the Lambda-Mu-Sigma approach; BD: bronchodilator
Fig. 2 Diagnostic criteria box for patients diagnosed with respiratory diseases
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